The newly issued patents cover a key cancer detection component of the M-Vu CAD system. Together, they include the ability to find suspicious looking calcification clusters and areas with spiculations, which make the system sensitive to finding areas of interest that are consistent with cancer.

This is accomplished without overwhelming the radiologists with false marks, which has historically plagued mammography CAD systems. VuCOMP has another seven patents pending related to its breast cancer detection products.

"These important new patents validate our strategy to pursue and obtain broad patent protection for our cutting-edge technology, and further extends an already strong intellectual property estate surrounding computer-aided detection of breast cancer," said Barry Burgdorf, Chief Operating Officer, VuCOMP.

VuCOMP’s M-Vu CAD system was the first mammography CAD product to meet the rigorous FDA standard that recommends comprehensive reader studies to prove the effectiveness of CAD systems.

"The new patents continue to distinguish VuCOMP as a pioneer in the development of the most advanced CAD system for mammography," said James Pike, President and Chief Technology Officer, VuCOMP. "Our commitment to advancing our technology and adding to our intellectual property estate delivers tremendous value to our customers, patients and investors."

US patents can be viewed on the US Patent and Trademark Office website at VuCOMP’s newly granted patents include US Patent VUC-007 for Microcalcification Detection Classification in Radiographic Images, and VUC-010 for Spiculated Malignant Mass Detection and Classification in Radiographic Images.